Novus Therapeutics (Tokai Pharmaceuticals) ^{Priced, Nasdaq: NVUS}

Biotech developing small molecule therapies for prostate cancer.

Industry: Health Care

First Day Return: +58.4%

NVUS

Biotech developing small molecule therapies for prostate cancer.

IPO News for Novus Therapeutics (Tokai Pharmaceuticals)

US IPO Pricing Recap: Alibaba pops 38%, represents one third of 2014 IPO market proceeds 09/19/14
Civitas falls below IPO price and Tokai Pharmaceuticals soars 09/17/14
Tokai Pharmaceuticals prices upsized IPO at $15, the high end of the range 09/17/14

IPO Data
IPO Date	09/16/2014
Offer Price	IPO Intelligence Only
Price Range	IPO Intelligence Only
Offer Shares (mm)	IPO Intelligence Only
Deal Size ($mm)	$97
Lock-Up Date	IPO Intelligence Only
Street Research	IPO Intelligence Only

Underwriters
IPO Intelligence Only

Company Data
Headquarters	Cambridge, MA, United States
Founded	2004
Employees at IPO	17
Website www.tokaipharma.com

IPO News for Novus Therapeutics (Tokai Pharmaceuticals)

Novus Therapeutics (Tokai Pharmaceuticals) (NVUS) Performance